Julie Simmonds

Matthew Larew

Brendan Smith

Chad Wiatrowski

Mark Massaro

Matthew Hewitt

Rohan Walcott

Daniel Arias

Hannah Hefley

Jacob Johnson

Matt Larew

Paul Cuddon

- **MaxCyte** has signed a **Strategic Platform License (SPL) agreement** with **Moonlight Bio**, a preclinical-stage biotechnology company focused on developing T cell therapies for solid tumors.  **[1287098_5500eb8f16934a438c6eb8f90a6ce816_0]** **[1287098_5500eb8f16934a438c6eb8f90a6ce816_1]** 
- Moonlight Bio will utilize MaxCyte's **Flow Electroporation® technology and ExPERT™ platform** for the scalable development and manufacturing of its T cell therapy pipeline.  **[1287098_5500eb8f16934a438c6eb8f90a6ce816_0]** 
- Under the SPL, MaxCyte will receive **annual licensing fees and program-related revenue** in exchange for granting Moonlight Bio non-exclusive research, clinical, and commercial rights to its technology.  **[1287098_5500eb8f16934a438c6eb8f90a6ce816_0]**

MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio

- On **September 22, 2025**, MaxCyte, Inc. announced an operational restructuring plan that includes a **reduction of approximately 34% of its global workforce**.  **[1287098_0001104659-25-092162_mxct-20250922xex99d1.htm:0]** **[1287098_0001104659-25-092162_mxct-20250922x8k.htm:1]** 
- This restructuring is projected to result in **annualized cost savings of approximately $13.6 million**, with these savings expected to begin being realized in **Q4 2025**.  **[1287098_0001104659-25-092162_mxct-20250922xex99d1.htm:0]** **[1287098_0001104659-25-092162_mxct-20250922x8k.htm:1]** 
- The company anticipates incurring **approximately $2.9 million in aggregate pre-tax, cash charges** related to the plan, primarily during the third quarter of 2025.  **[1287098_0001104659-25-092162_mxct-20250922x8k.htm:1]** 
- MaxCyte reiterated its 2025 outlook, expecting **core revenue to be flat to down approximately 10% compared to 2024**, and year-end cash, cash equivalents, and investments to be **at least $155 million**.  **[1287098_0001104659-25-092162_mxct-20250922xex99d1.htm:0]**

MaxCyte Announces Operational Restructuring and Workforce Reduction

MAXCYTE (MXCT)